Preparation and method for decreasing early embryonic lethality in cattle

FIELD: animal science, veterinary science.

SUBSTANCE: the suggested preparation for decreasing early embryonic lethality in cows contains vitamins A, D3 and E, potassium iodide and ACD of the 2nd fraction, sunflower or peach oil at the following ratio of components: vitamin A 15000-24000 IU, vitamin D3 20000-32000 IU, vitamin E 20-36 mg, potassium iodide 12 mg, ACD of the 2nd fraction 0.12 ml, sunflower or peach oil up to 1 ml. The innovation deals with intramuscular injection of the above-mentioned preparation during the period since the 5th to the 7th d after insemination in cows. The innovation provides decreased level of early embryonic lethality in cattle at simultaneous decrease of labor intensity of the method applied.

EFFECT: higher efficiency.

2 cl, 3 ex, 2 tbl

 

The invention relates to animal husbandry, in particular to methods of breeding animals, and in particular to methods of reducing early embryonic mortality in cattle.

Known means VDPS to enhance the reproductive activity of animals and reduce embryonic death of offspring, representing Tris-(2 oxyethyl) ammonium herio-cratchett [o-Krez oxyacetic-Tris-(2-oxyethyl) ammonium (2-CH3With6H4OCH2Soo)-(NH(CH2CH2OH)3)+]. The drug is produced either by mixing alcoholic solutions of reagents followed by heating the reaction mixture to a boil, or fusion on-resocialise acid Tris-(2-oxyethyl) amine (autospid. The USSR №704618 And 61 To 31/185, a 01 K 67/00, 1979).

The drug has allowed to receive the increased fertility of the lambs with high viability. However, this drug has not found use in cattle.

Known vitamin preparation at oil solution containing 1 ml of 25,000 IU of vitamin E. Threefold introduction vitamin E 2.6 and 12 days after insemination dose of 5 ml was increased springing cows 10.5 14.9 per cent (Columns V.M., Bakhmut, L.N., Rymarov L.D., Halitosis O.L. Improving the reproductive function of cows by application of vitamin preparations. // Reports of the agricultural Sciences. No. 2. - 1984. - p.19-21).

Known is repeat enhances the metabolic and mitotic processes in the endometrium, creating favorable conditions for the supply of the embryo in the early stages of development and subsequent implantation. In addition, it contributes to increasing the functional activity of the yellow body, which increases the level of endogenous progesterone. Lack of preparation is that vitamin E does not directly affect the status of the immune system and mineral metabolism, and for the development of the embryo is of great importance to the security of the mother of macro - and microelements, the lack of which can also lead to death of the embryo in the early stages of development.

A known method of reducing early embryonic mortality in cattle, namely, that in 5-8 days after insemination of cows injected once 10 µg buserelina, while fertility was increased by 6-12% (D.P. Ryan, E. Kopel, Boland M.P. Pregnancy rates in dairy cows following the administration of a GnRH analogue at the time of artificial insemination or at midcycle post insemination // Theriogenology. - 1991. - V.36. No. 3. - pp.367-377). The advantage of this method is ease of use, it allows you to enhance the functional activity of the yellow body of pregnancy by increasing the excretion of luteinizing hormone by the pituitary gland and increase endogenous levels of progesterone. However, this method is not capable of regulating metabolic processes in the endometrium that in some cases, also the drive of the t to embryonic mortality due to poor coverage of the embryo with nutrients prior to implantation and during it. In some cases, the immune system of the mother treats the embryo as the antigen, which ultimately also leads to his death. The above method is also not able to influence the immune status of the parent body.

A known method of reducing early embryonic mortality in cattle, including a single injection of progesterone in doses of 250-750 mg for 7-10 days after insemination (Lukaszewski I., K. Marcinkowski, Krolinski I. Wplyw egzogennogo progesteronu wyniki na zacielen w swietle badan klinicznych i endokrinologicznych // Med. Wet. - 1993. - V.49. No. 7. - S.322-323). This method helped to increase the fertility of 16.6%. The advantage of this method is the ability to quickly increase the level of endogenous progesterone, which inhibits the motility of smooth muscles of the uterus and promotes implantation of the embryo in the wall. But when using this method it is impossible to influence morphofunctional state structures of the endometrium and its immune status.

The closest in technical essence and the achieved result is the drug "Thevitamin" and the method of its use for the prevention of embryonic mortality in cattle (Mingazov T.A. Prevention of embryonic mortality in cattle by trephination // Bulletin of agricultural science of Kazakhstan. - 1976. No. 3. - C-82).

Cows 7-8 months of pregnancy on the second calving is nutramigen was injected at 5 ml "Thevitamin" - sterilized oil solution of vitamin a (15 tysia 1 ml), D3(20 Tisa) and E (10 mg) with an interval of 6-7 days, about 60 days before calving, postpartum, and within 30 days after insemination. In the experimental animals compared to control survival of embryos to 30-33, and 60-65 days after insemination was 25% higher. Thus, the use of "Thevitamin" contributed to reducing the rate of early embryonic mortality in cows. However, this method is relatively time-consuming.

When creating the present invention, the objective was to improve the reproductive function of animals, i.e. in reducing early embryonic mortality and improve pregnancy of cows.

The technical result of the invention is to reduce the level of early embryonic mortality in cattle and complexity of the tool.

The technical result of the invention is achieved by the fact that the proposed means to reduce early embryonic mortality in cows, including 6 components: known vitamins a, D3E and vegetable oil, in addition, additional potassium iodide and ASD 2nd faction, and as oil means includes sunflower oil or peach, in the following ratio of components:

tr>
Vitamin a15000-24000 ME
Vitamin D320000-32000 ME
Vitamin E20-36 mg
Potassium iodide12 mg
ASD 2nd faction0,12 ml
Sunflower or peach oilTo 1 ml

A method of reducing early embryonic mortality in cattle, including intramuscular injection of biologically active drug in the dose of 5 ml, the peculiarity of which is that as a biologically active drug use tool according to claim 1 once in the period from 5 to day 7 after insemination of cows.

The drug is prepared per 1 ml as follows: dissolve in oil vitamins: vitamin a 15000-24000 ME, the vitamin D320000-32000 ME, vitamin E 20-36 mg, to the resulting solution was added 12 mg of potassium iodide, 0,12 ml ASD fractions 2 and bring the volume of sunflower or peach oil to 1 ml of the Components are mixed for 15 minutes in an ultrasonic mixer.

The drugs are based on the integrated influence of fat-soluble vitamins and potassium iodide on the metabolic processes in the body of the mother and fetus. Vitamin a is involved in phosphate, carbohydrate, lipid metabolism, regulates oxidative processes, regulates the growth of epitheli the selected tissue, including epithelium of the endometrium. Vitamin D is involved in the regulation of energy and mineral exchanges, promotes the absorption of calcium and phosphorus. Vitamin E is involved in the regulation of carbohydrate and lipid metabolism, oxidative reactions in the body. Iodine is involved in the metabolism as a component of thyroid hormones, contributes to fermentoobrazovanija, supports protective reaction of the organism, accelerates the formation of new cells, a positive effect on fetal development.

Blended with the drug ASD faction 2" is a product of the destructive distillation of raw materials of animal origin. Contains compounds with active sulfhydryl group, derivatives of aliphatic amines, carboxylic acids, aliphatic and cyclic carbohydrates, derivatives of amides and water. ASD faction 2 is a potent immunomodulator that helps to normalize the body's immune response of the mother.

The use of the proposed tools 5-7 days after insemination due to the fact that this period is the most critical for embryo development, because at this time the nutrition of the embryo is entirely dependent on the secretion of the glands of the endometrium and the embryo prepares to launch in the wall of the uterus.

Example 1. At the dairy complex "Batabano" agro JSC "Shchapovo-Agrotech" Moscow is the area in 2000 on cows of black-motley breed Holstein breeding studied the efficacy of the proposed drug, depending on the point in time after insemination of cows.

Used the drug, including 1 ml: vitamin a - 15000 ME, the vitamin D3- 20000 ME, vitamin E 20 mg, potassium iodide 12 mg, DCA 2nd fraction of 0.12 ml of sunflower oil to 1 ml.

According to the principle analogues was chosen 9 groups of cows with an average milk yield of about 6000 kg of milk per lactation, 20 goals each. The drug was injected once intramuscularly at a dose of 5 ml of 2-nd, 3 rd, 4 th, 5 th, 6 th, 7 th, 8 th, 9 th and 10 th days after insemination of cows. The results are shown in table 1.

Found that the best result is 80-85% of pregnancies obtained using drugs on 5-7th days after insemination of cows.

Table 1
The efficacy of the claimed drug depending on the point in time after insemination of cows
IndicatorsThe day the drug after insemination
2nd3rd4th5th6th7th8th9th10th
The number of cows in the group202020202020202020
Of them became pregnant, goals1214 15171616111011
Share springing from the number of inseminated, %60,0±10,9570,0±10,2475,0±9,6885,0±7,98*80,0±8,9480,0±8,9455,0±11,1250,0±11,1855,0±11,12
*P<0,1

Example 2. At the dairy complex "Batabano" agro JSC "Shchapovo-Agrotech" Moscow region in 2002 studied the effect of the requested drug to reduce embryonic mortality in dairy cows of black-motley breed Holstein breeding depending on the dose.

Used the drug, including 1 ml: vitamin a - 20000 ME, the vitamin D3- 25000 ME, vitamin E - 36 mg, potassium iodide 12 mg, DCA 2nd fraction of 0.12 ml of sunflower oil to 1 ml.

According to the principle analogues was picked up 8 groups of cows with an average productivity of about 6000 kg of milk per lactation, 20 goals each. The group No. 1 was the control and the animals in this group have been processed. Cows in the second group, the drug was administered at a dose of 2 ml 3 3 ml, 4 th 4 ml, 5, 5 ml, 6 th 6 ml, 7-th, 7 ml, 8 - 8 ml. of All the animals of these groups, the drug was injected once intramuscularly on day 5 after insemination. The results are presented in t the blitz No. 2.

Best result - pregnancy 80,0% achieved with the claimed preparation in a dose of 5-6 ml as the optimal adopted a dose of 5 ml

Table 2
Efficacy of different doses of the claimed preparation in the introduction on the 5th day after insemination of cows
IndicatorsThe control animals not exposed to processing)Dose
2 ml3 ml4 ml5 ml6 ml7 ml8 ml
The number of cows in the group2020202020202020
Of them became pregnant, goals1110121416161412
Share springing from the number of inseminated, %55,0±11,1250,0±11,1860,0±10,9570,0±10,2480,0±8,94*80,0±8,94*70,0±10,2460,0±10,95
*P<0,1

Example 3. In the GEA them. Frunze Bel the city area during the 2002 livestock 700 cows of different ages was studied the effect of the requested drug to reduce early embryonic mortality in dairy cows of black-and-white breed, with average productivity of per lactation 5600 kg of milk.

Used the drug, including 1 ml: vitamin a - 24000 ME, the vitamin D3- 32000 MB, vitamin E - 36 mg, potassium iodide 12 mg, DCA 2nd fraction of 0.12 ml of sunflower oil to 1 ml.

The drug was administered for 5-7 days after insemination dose of 5 ml intramuscularly once. As control served cow equivalents by type of housing, feeding and productivity in the 1800 number of goals with spontaneous hunting, not exposed to processing. Pregnancy was determined by rectal method 60 days after insemination. The level of pregnancy in cows treated with the claimed drug was higher than the control at 18%.

The invention is applicable in dairy cattle: dairy farms and complexes, as well as in private farms of the population.

1. Means for reducing early embryonic mortality in cattle, including vitamins a, D3and E and vegetable oil, characterized in that it further includes potassium iodide and ASD 2nd faction, and as oil comprises sunflower oil or peach, in the following ratio of components:

Vitamin a15000-24000 ME
Vitamin D320000-32000 ME
Vitamin E20-36 mg
Iodine ka is s 12 mg
ASD 2nd faction0,12 ml
Sunflower oil or peachTo 1 ml

2. The way to reduce early embryonic mortality in cattle, including intramuscular injection of biologically active drug in the dose of 5 ml, characterized in that the biologically active drug use tool according to claim 1, and the introduction is carried out once in the period from 5 to day 7 after insemination of cows.



 

Same patents:

FIELD: medicine, anesthesiology, obstetrics.

SUBSTANCE: the present innovation deals with operative parturition in pregnant women in case of gestosis of average severity degree. Thus, it is necessary to fulfill spinal anesthesia due to injecting marcaine. Immediately after marcaine injection one should intravenously inject 8 mg dexametason. On developing a regional block before the onset of operation it is necessary to carry out intravenous infusion of dalargin in the quantity of about 40-50 mcg/kg/h. Infusion should be continued during the whole period of operative interference and for about 10-20 min after operation. The innovation enables to fulfill adequate anesthesia that prevents the impact of operational stress not due to the blockade of nociceptive system only, but due to stimulation of natural stress-limiting systems of the body ,as well.

EFFECT: higher efficiency.

2 ex, 3 tbl

FIELD: organic chemistry, amino acids.

SUBSTANCE: invention proposes the novel derivatives of phenylalanine of the formula (I) and (II) possessing with antagonistic activity with respect to α4-integrin. Derivatives of phenylalanine are used as therapeutic agents in different diseases associated with α4-integrin.

EFFECT: valuable medicinal properties of compounds.

37 cl, 30 tbl, 215 ex

FIELD: medicine, angiosurgery.

SUBSTANCE: one should fulfill rotational osteotrephination of limb's bones followed by carrying out pharmacotherapy. Moreover, at inferior limbs it is necessary to conduct tibial osteotrephination in metaepiphyseal parts together with metatarsal bones of inferior limbs and each toe's phalanx. At superior limbs one should fulfill osteotrephination of metacarpal bones and each finger's phalanx by moving from proximal phalanx towards distal one successively. Moreover, in case of symmetrical arterial lesions in limbs osteotrephination should be fulfilled in single stage and then, one should inject 0.5%-novocaine solution at the dosage of 20 ml followed by 20%-sodium oxybutyrate solution at the dosage of 10 ml once/3 d, intramuscularly, into area of maximal ischemic pains in every affected limb alternately, the course consists of 10 procedures. The innovation suggested enables to increase the volume of collateral muscular-periosteal blood circulation and reconstruct functional activity of affected limbs.

EFFECT: higher efficiency of therapy.

4 dwg, 2 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: the present innovation deals with stable peroral solid composition of ramosetron or its pharmaceutically acceptable salt. The composition includes one or several components chosen out of the groups including aliphatic carboxylic acid or its ester, hydroxycarboxylic acid or its ester, acidic amino acid, enolic acid, aromatic carboxylic compound or its ester and high-molecular substance that contains carboxylic group. Such an innovation refers to the method for stabilizing ramosetron composition. The suggested innovation provides stability of ramosetron composition under conditions of increased temperature and humidity, especially at low content of active component.

EFFECT: higher efficiency of application.

14 cl, 10 ex, 6 tbl

FIELD: medicine.

SUBSTANCE: method involves introducing biomaterial as injection into injured region. Dispersed Alloplant biomaterial being regeneration stimulator with prevailing hyaluronic acid content in extracellular matrix is used. The regeneration stimulator is diluted with local anesthetic like lidocain or novocain solution in the proportion of 150-300 mg of Alloplant per 10 ml of the solution. The injections are perifocally administered in 1-6 points.

EFFECT: reduced patient immobilization period; high regenerate quality.

2 cl

FIELD: medicine, otorhinolaryngology.

SUBSTANCE: one should carry out sanitizing and reconstructive operation of middle ear and fill in anthromastoidal cavity with a transplant, moreover, as a transplant one should apply biositall granules pre-impregnated for about 30-40 min in solution of preparation named "Human diploid cell culture for substitutional therapy", and with the same solution it is necessary to irrigate the whole wound surface. The present innovation enables to accelerate reparative processes, improves transplant's adaptation and shortens the number of postoperational complications.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, pharmaceutical industry, adhesive materials for surgery.

SUBSTANCE: claimed new tissue adhesive represents latex-based resin composition and contains butylacrylate acrylonitrile latex, polyvinyl alcohol aqueous solution as viscosity controller and ammonia aqueous solution as pH controller.

EFFECT: non-toxic adhesive with high adhesion ability to living tissue, biocompatibility and biodegradability, bactericidal and haemostatic properties, stability to sterilization and storage.

2 cl, 1 tbl

FIELD: medicine, pharmaceutical industry, adhesive materials for surgery.

SUBSTANCE: claimed new tissue adhesive represents latex-based resin composition and contains pharmaceutical additives, polyvinyl alcohol aqueous solution as viscosity controller and ammonia aqueous solution as pH controller. Said adhesive composition has viscosity from 7000 to 13000 mPa/s, pH from 7.1 to 7.4 and working temperature from 15°C to 50°C.

EFFECT: adhesive with high adhesion ability to living tissue, biocompatibility and biodegradability, bactericidal and haemostatic properties, stability to sterilization and storage.

5 cl, 1 tbl

FIELD: veterinary medicine and veterinary pharmacology.

SUBSTANCE: invention relates to application of compounds combining properties of selective antagonists of dopamine D2 receptor and agonists of 5-HT1A receptor, in particular (R)-(-)-2-[5-(4-fluorophenyl)-3-piridylmethylaminomethyl]-chromane or pharmaceutically acceptable salts thereof, or N-(4'-fluoro-3-biphenylmethyl)-N-2-(3-cyanophenoxyethyl)-amine or pharmaceutically acceptable salts thereof. Said compounds are useful in veterinary medicine for treatment of self-directed traumatic disorders, associated with behavioral stress-factors, and/or compulsive disorders, associated with behavioral stress-factors, and/or anxiety, associated with behavioral stress-factors.

EFFECT: effective method for treatment and prophylaxis of disorders, associated with behavioral stress-factors.

6 cl, 3 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to inhibitor of matrix metalloproteinases representing extract from fungus Canoderma atrum obtained by using of water and/or lower alcohols as extractant. Also disclosed are pharmaceutical agent for inhibition of tumor metastasis containing of 0.03-10 wt.% of abovementioned extract and foodstuff containing claimed extract.

EFFECT: improved inhibitor of matrix proteinases.

3 cl, 18 ex, 4 tbl

FIELD: veterinary science.

SUBSTANCE: the present innovation refers to medicinal preparations applied for treating puerperal purulent-catarrhal endometritis and mastitis in cows and to the method of applying the present medicinal preparations. The suggested preparation for treating puerperal purulent-catarrhal endometritis, serous, seroso-catarrhal and subclinical mastitis in cows includes 1.4-di-N-oxide 2.3-bis-(oxymethyl) quinoxaline, trecresan (cresacin), dimethyl sulfoxide, propandiol 1.2 at the following ratio, (g/%): 1.4-di-N-oxide 2.3-bis-(oxymethyl) quinoxaline 1.0-1.2; trecresan (cresacin) 3.0-3.18; dimethyl sulfoxide 10.0-10.5; propandiol 1.2 20-25; distilled water - the rest. The innovation deals with intra-uterine introduction of the preparation suggested at the dosage of about 70-100 ml once daily for about 4-5 d. Moreover, this preparation should be introduced into affected part of the udder at the dosage of 10 ml once daily for 3-5 d. The innovation enables to shorten the multiplicity of introduction and accelerate the terms of recovery.

EFFECT: higher efficiency of therapy.

4 cl, 2 ex, 6 tbl

FIELD: veterinary science.

SUBSTANCE: the present innovation refers to medicinal preparations applied for treating puerperal purulent-catarrhal endometritis and mastitis in cows and to the method of applying the present medicinal preparations. The suggested preparation for treating puerperal purulent-catarrhal endometritis, serous, seroso-catarrhal and subclinical mastitis in cows includes 1.4-di-N-oxide 2.3-bis-(oxymethyl) quinoxaline, trecresan (cresacin), dimethyl sulfoxide, propandiol 1.2 at the following ratio, (g/%): 1.4-di-N-oxide 2.3-bis-(oxymethyl) quinoxaline 1.0-1.2; trecresan (cresacin) 3.0-3.18; dimethyl sulfoxide 10.0-10.5; propandiol 1.2 20-25; distilled water - the rest. The innovation deals with intra-uterine introduction of the preparation suggested at the dosage of about 70-100 ml once daily for about 4-5 d. Moreover, this preparation should be introduced into affected part of the udder at the dosage of 10 ml once daily for 3-5 d. The innovation enables to shorten the multiplicity of introduction and accelerate the terms of recovery.

EFFECT: higher efficiency of therapy.

4 cl, 2 ex, 6 tbl

FIELD: medicine; physiotherapy; urology.

SUBSTANCE: method can be used for complex treatment of patients suffering from erectile prostatitis complicated with symptoms of erectile dysfunction. Perineum is subject to SMC-therapy proserin electrophoresis simultaneously with pulse magnetic field. Combined effect is performed within 2 steps. At first step, SMC-therapy proserin electrophoresis at perineum is performed at rectified mode of SMC-I (constant modulation) sort of operation at modulation frequency of 20-30 Hz, depth of modulation of 75-100%, current strength of 20-30 mA and duration of influence of 5-7 minutes. Simultaneously perineum area is subject to rectangular pulse magnetic field during 5-7 minutes. Frequency of rectangular pulse magnetic field equals to 20-30 Hz, magnetic induction is equal to 20-30 tesla. At second step the effect of proserin electrophoresis is performed at rectified mode IV (permanent frequency) of operation with modulation frequency of 20-30 Hz., depth of modulation of 100% and higher, duration of sendings 4s:6s and bipolar rectangular pulse magnetic field is used for influence during 8-10 minutes. Frequency of bipolar rectangular pulse magnetic field equals to 20-30 Hz. Longer period of remission is observed due to usage of combined influence of proserin electrophoresis and magnetic field at mentioned modes of operation.

EFFECT: improved electrophoresis permeability of cutaneous coverings; increased efficient concentration of proserin in prostate.

4 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out vacuum massage of prostate with an apparatus. Tampons with 40-45°C hot sulfide mud taken from Sucsun pond are additionally rectally introduced for 20-30 min. The total treatment course is 8-10 procedures long. Daily microenemas are prescribed with mineral water at 36°C in a 10 procedures long course.

EFFECT: enhanced effectiveness of treatment.

FIELD: medicine, gynecology.

SUBSTANCE: during the first half of the day it is necessary to dissolve 10 mg cortexin and 4 mg nicergolin in10 ml of novocain solution or physiological solution, then this quantity of solution should be divided into 10 portions to be injected paravertebrally for the depth of about 0.7-1.0 cm in projection of C4-C7 segments. Duration of therapy corresponds to 10 d. The innovation provides modulation of metabolism of neuromediators and antioxidant systems in combination with activation of cerebral neurotrophic processes and, as a result, normalization of neuro-autonomic symptomatics for 6 mo that enables to apply it as alternative of hormonal therapy in case of climacteric syndrome.

EFFECT: higher efficiency of therapy.

2 ex, 2 tbl

FIELD: medicine, gynecology.

SUBSTANCE: during the first half of the day it is necessary to dissolve 10 mg cortexin and 4 mg nicergolin in10 ml of novocain solution or physiological solution, then this quantity of solution should be divided into 10 portions to be injected paravertebrally for the depth of about 0.7-1.0 cm in projection of C4-C7 segments. Duration of therapy corresponds to 10 d. The innovation provides modulation of metabolism of neuromediators and antioxidant systems in combination with activation of cerebral neurotrophic processes and, as a result, normalization of neuro-autonomic symptomatics for 6 mo that enables to apply it as alternative of hormonal therapy in case of climacteric syndrome.

EFFECT: higher efficiency of therapy.

2 ex, 2 tbl

FIELD: medicine, gynecology.

SUBSTANCE: before operation it is necessary to sample patient's blood to divide it into plasma and blood cells. Blood plasma should be divided into three parts and frozen. After operation one should intravenously reinfuse by drops erythrocytic mass incubated for 30 min at 37° C with 2 g lendacyn followed by further lendacyn injection per 1g intramuscularly during the next 6 d. Blood plasma should be portionally defrosted, incubated at 37° C with: 10000 U trasilol, 0.15 g lisozyme, 0.02 g novocain, after incubation it is necessary to add 100 ml gelatinol to be reinfused for a patient on the 2nd, 4th and 6th d against the onset of therapy course through microirrigator withdrawn out of posterior arch during operation. The innovation provides combined impact of antibiotics upon pathological focus biotransformed with erythrocytic mass and local immunomodulating and resolving effect and, thus, decreased formation of adhesions, fistulas and cicatrices.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to novel amino- and hydroxy-derivatives of phenyl-3-aminomethylquinolone-2 of the general formula (1):

wherein R1, R2, R3 and R4 are independently similar or different and R1 is chosen from hydrogen atom (H), Alk, OAlk; R2 is chosen from H, Alk, OAlk, -OCF3; R3 is chosen from H, Alk, OAlk, -SCH3; R4 is chosen from H. Alk, OAlk, or R2 and R3 are chosen from -(CH2)3, -OCH2O-, -OCH2CH2O-; R5 means H or Alk; R6, R7 and R9 mean H; R8 is chosen independently from the following substitutes:

wherein n = 1, 2, 3; Het represents furan; R represents hydrogen atom or alkyl. In case of hydroxy-derivatives at least one among R6, R7, R8 or R9 is -OH and other represent H. Also, invention relates to methods for synthesis of these compounds and to a pharmaceutical composition based on these compounds inhibiting activity of NO-synthase. Invention provides preparing novel compounds and pharmaceutical compositions based on thereof in aims for treatment of diseases associated with hyperactivity of phagocytizing cells, for example, rheumatic arthritis, asthma and others.

EFFECT: improved preparing method, valuable medicinal and biochemical properties of compounds and pharmaceutical composition.

32 cl, 1 tbl, 132 ex

FIELD: medicine.

SUBSTANCE: method involves determining lymphocyte CD 56+ in peripheral blood before planned pregnancy. The content exceeding norm, lymphocytoimmunotherapy courses are applied with donor lymphocytes. The courses are applied at the fifth-eighth day of fertility cycle until normal lymphocyte CD 56+ values become restored. Pregnancy being proved, lymphocytoimmunotherapy courses are applied with ultrasonic examination results having in view. Choriohypoplasia being available, the courses are applied every 2 weeks. Chorion thickness being in conformity with gestation age, the courses are applied every 3-4 weeks to 12-14 pregnancy weeks.

EFFECT: adequate chorion and placenta development.

2 tbl

FIELD: pharmaceutical industry.

SUBSTANCE: claimed composition for sublingual application contains apomorphine as active ingredient and succinic acid as apomorfine stabilizer and filler, as well as other additives.

EFFECT: sublingual tablet with sufficient strength and resolvability.

4 cl, 1 tbl, 2 ex

FIELD: biotechnology, oncology.

SUBSTANCE: invention relates to a novel prepared human melanoma cellular line mel Kor that possesses stable cultural and morphological indices and stored in the Specialized collection of cellular cultures of Cytology institute at number PKKK (P) 687D. The cellular line is characterized by expression of melanoma (differentiating) markers - CD-63, HMB-45, HMW, MelanA and Tyrozinaza and cancer-testicular marker MAGE-3 also and absence of histo-compatibility antigens of the first and the second class. The cellular line can be used for creature of antitumor (all-cell, genetic engineering) vaccines used in treatment of melanoma and other malignant neoplasms. Using the invention provides preparing the novel effective antitumor vaccine and can be used in medicine for vaccine therapy of malignant neoplasms.

EFFECT: valuable medicinal properties of cellular line.

1 tbl, 2 ex

Up!